Summary
This 2024 narrative review in Life Sciences examines the preclinical and clinical evidence base for antibody-drug conjugates (ADCs) targeting nectin-4, a cell adhesion molecule with relevance to several cancer types. The authors synthesise data on mechanism of action, efficacy endpoints, and safety considerations to characterise the therapeutic potential of this emerging drug class. As a review of oncology therapeutics, the work is tangential to the Vitagri Pulse Brain's core remit but may be relevant to broader food systems and human health intersections.
UK applicability
This oncology-focused immunotherapy review has limited direct applicability to UK farming systems or food production. Its relevance to Vitagri's mission (farm systems, soil health, nutrient density) is indirect at best and does not address food or agricultural science.
Key measures
As suggested by the title, the review likely assessed preclinical efficacy data, clinical trial outcomes, adverse event profiles, and regulatory/development status of nectin-4-directed ADCs
Outcomes reported
The study synthesises preclinical and clinical evidence for nectin-4-directed antibody-drug conjugates (ADCs) as a therapeutic approach. The review evaluated efficacy, safety, and clinical development status of nectin-4-targeting agents across multiple cancer types.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.